Transdermal treatment of type 11 diabetes
Overview of innovation
This technology relates to the transdermal treatment of diabetes. In particular, to a formulation for the transdermal delivery of the photoactive antidiabetic agent diosgenin that is encapsulated and protected by an oil-in-water nanoemulsion matrix for the treatment of type 11 diabetes Mellitus. There are significant complications and side effects posed by parental drugs or oral route of delivery, including among others invasive drug delivery systems.
Advances have been made to improve drug delivery and alleviate these challenges. These advances include drug delivery systems that deliver drugs at a constant rate and sustained release, reduced side effects and frequent doses.
Type of Intellectual Property protection
Innovation Opportunity Type
Human health and social work activities
Pharmaceuticals and Biopharmaceuticals
Technology Readiness Level
TRL 5 – Prototype tested in a controlled environment